Skip to main content

Maui Derm NP+PA Summer, 2025

Filter
Close
Content type:
Bimekizumab efficacy and safety through 5 years in patients with moderate to severe plaque psoriasis in the US and Canada
Blauvelt Andrew, Khattri Saakshi, Rich Phoebe, et al.
Poster
Bimekizumab maintenance of response at every visit over 4 years in patients with psoriasis achieving clear skin at Week 16: Results from four phase 3 trials
Lebwohl Mark, Warren B. Richard, Foley Peter, et al.
Poster
Bimekizumab impact on flare in hidradenitis suppurativa over 2 years: Data from BE HEARD EXT
Naik B Haley, Daveluy Steven, Errol Prens, et al.
Poster